Neuburgh Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

Neuburgh Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$307K	Buy	11,186 +408	+4%	+$12.1K	0.01%	582
2019 Q2	$357K	Hold	10,778	–	–	0.01%	549
2019 Q1	$378K	Hold	10,778	–	–	0.01%	523
2018 Q4	$358K	Hold	10,778	–	–	0.01%	482
2018 Q3	$543K	Buy	10,778 +1,972	+22%	+$97.4K	0.02%	439
2018 Q2	$527K	Hold	8,806	–	–	0.02%	411
2018 Q1	$403K	Buy	8,806 +374	+4%	+$15.6K	0.01%	466
2017 Q4	$336K	Buy	8,432 +1,768	+27%	+$69.9K	0.01%	521
2017 Q3	$266K	Buy	6,664 +884	+15%	+$38.3K	0.01%	537
2017 Q2	$249K	Buy	5,780 +2,720	+89%	+$96.8K	0.01%	531
2017 Q1	$96K	Buy	3,060 +306	+11%	+$8.2K	﹤0.01%	623
2016 Q4	$70K	Buy	+2,754	New	+$61.5K	﹤0.01%	673

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Neuburgh Advisers's SUPN Position: Q3 2019 in Review

Neuburgh Advisers increased its Supernus Pharmaceuticals (SUPN) stake by 3.8% in Q3 2019, buying an estimated $12.1K and bringing the position to 11,186 shares worth $307K. The position accounts for 0.01% of the portfolio, ranked #582.

Neuburgh Advisers first reported a position in SUPN in Q4 2016 and has held it in 12 quarters since. The position peaked at $543K in Q3 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Neuburgh Advisers held 11,186 shares of Supernus Pharmaceuticals worth $307K as of Q3 2019.
Neuburgh Advisers bought 408 Supernus Pharmaceuticals shares in Q3 2019, an estimated $12.1K.
Supernus Pharmaceuticals made up 0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #582 holding.
Neuburgh Advisers first reported a position in Supernus Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
Neuburgh Advisers's Supernus Pharmaceuticals position peaked at $543K in Q3 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.